查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916905

江之靈片市場：按產品類型、治療領域、生產商類型、通路和最終用戶分類－2026-2032年全球預測

Jiangzhiling Tablets Market by Product Type, Therapeutic Area, Manufacturer Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，江之靈片劑市場價值將達到 9,386 萬美元，到 2026 年將成長至 1.0451 億美元，到 2032 年將達到 1.2603 億美元，複合年成長率為 4.30%。

關鍵市場統計數據
基準年 2025 9386萬美元
預計年份：2026年 1.0451億美元
預測年份 2032 1.2603億美元
複合年成長率 (%) 4.30%

對江之靈片進行深入分析，分析內容涵蓋臨床需求、製劑特性以及影響其策略選擇的商業性環境。

江之靈片憑藉其獨特的製劑特性和標靶治療治療應用，已成為心血管和代謝治療領域獨樹一幟的治療方法，吸引了臨床醫生、支付方和生產商的廣泛關注。隨著治療模式日益重視患者依從性和差異化釋放曲線，江之靈片的市場定位恰好滿足了臨床對持續療效的需求和商業性上對可靠供應的迫切需求。本介紹將產品置於更廣泛的治療需求、監管審查和分銷複雜性的背景下，說明讀者了解戰略決策背後的關鍵考慮因素。

更嚴格的監管、多元化的通路以及以患者為中心的製劑優先策略將如何重塑江之靈片的商業性和臨床格局

由於監管政策的變化、通路的演變以及供應鏈監管的加強，循環系統藥物和口服藥錠市場格局正在變革性變化。新的生產模式優先考慮在地化生產的靈活性和日益嚴格的品管，而數位化管道的興起則持續加劇通路的碎片化。這些變化正在重塑江之靈等產品的研發、核准和交付方式，需要研發、生產和商業化等各個環節的相關人員做出相應的調整。

評估截至2025年的關稅如何加強了江之菱價值鏈的供應鏈重組、籌資策略和製造本地化決策。

主要經濟體實施的關稅政策將持續到2025年，這進一步增加了藥品供應鏈的複雜性，影響成本、採購決策和策略性製造地。對於依賴進口原料藥和成品藥的產品而言，關稅相關的附加稅和合規要求正在增加採購成本，並促使企業重新評估供應商網路。為此，許多製造商正在評估近岸外包的可行性，以加快供應商選擇流程並降低貿易政策波動的風險。

要了解江之靈片市場，需要建立一套嚴謹的市場區隔框架，以揭示通路、患者群體、劑型、治療標靶和生產商概況如何影響策略重點。

要了解江之靈片市場，需要深入分析通路、終端用戶群、產品類型、治療應用和製造商類型等因素，這些因素都會對商業策略產生不同的影響。分銷管道涵蓋醫院藥房、線上藥房和零售藥房，其中醫院主導著組織採購流程，而線上管道則加快了患者獲取藥物的便利性。終端使用者因素則區分成人、老年人和兒童病患群體，進而影響臨床訊息、給藥方案和依從性計畫。

區域監管差異、報銷結構和生產能力如何影響江之靈片的打入市場策略和供應鏈策略

區域趨勢將對江之靈片的監管路徑、報銷機制和供應鏈設計產生重大影響，每個區域都面臨獨特的營運和商業挑戰。在美洲，嚴格的監管、激烈的醫保談判以及經銷商的高度參與共同影響著市場趨勢，促使企業更加重視臨床證據和強力的藥物監測，以確保產品被納入處方集目錄。同時，在歐洲、中東和非洲地區，監管協調與分散的醫保體系並存，市場格局呈現出多元化的特點，企業需要製定能夠應對各國採購和定價差異的適應性策略。

競爭格局分析表明，原廠品牌、國內外學名藥以及製劑技術是決定差異化和商業性發展勢頭的關鍵因素。

江津地區的競爭格局由成熟的原廠藥品牌和不斷擴張的非專利市場共同構成，二者各自提出了不同的策略要務。原廠藥品牌往往專注於差異化的臨床證據、全生命週期管理和高階定位，而非專利優先考慮成本競爭力、生產效率和建立廣泛的分銷網路。在學名藥領域，國內生產商傾向於利用低成本營運和接近性在地採購管道的優勢，而進口學名藥則可能透過提升品牌知名度、規範合規記錄或製劑技術來脫穎而出。

切實可行的策略重點，將配方創新、供應鏈韌性和通路特定的商業執行相結合，以確保競爭優勢。

產業領導者應採取整合策略，將製劑創新、供應鏈韌性和精準的商業性執行結合，以把握機會並降低風險。優先投資於緩釋製劑的研發可以帶來顯著的臨床優勢和用藥依從性提升，但必須輔以嚴格的穩定性測試和清晰的臨床溝通差異化。同時，供應商網路多元化和評估近岸外包方案可以降低貿易政策波動帶來的風險，並使原料藥和成品的前置作業時間更加可預測。

採用嚴謹的混合方法，結合與關鍵相關人員的直接對話、二次三角驗證和情境檢驗，以確保研究結果的穩健性和有效性。

本分析的調查方法結合了與主要相關人員的對話以及全面的第二手資料綜合分析，以確保對江之靈的市場環境有全面而深入的了解。一級資訊來源包括對臨床專家、供應鏈經理和商業負責人的結構化訪談，以獲取有關處方行為、採購趨勢和營運限制的第一手資訊。隨後，將這些定性研究結果與監管文件、已發表的臨床文獻和產品檢驗進行三角驗證，以檢驗技術和安全性聲明。

配方差異化、供應鏈韌性和精準商業化如何決定江之靈永續市場表現的策略整合分析

總之，江之靈片的市場環境是這樣的：基於製劑特性的臨床機會與重要的商業性營運挑戰交織在一起。緩釋技術和製劑改良為高血脂症和高血壓等治療領域的差異化提供了途徑，但成功取決於臨床證據、法規遵循和可靠的供應鏈的綜合運用。通路和終端用戶的多樣性進一步要求制定細緻打入市場策略，以平衡機構採購週期與零售藥局和線上藥局日益成長的影響力。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 江之靈片劑市場（依產品類型分類）

  • 緩釋片
    • 0.5克強度
    • 1克強度
  • 標準片劑
    • 0.5克強度
    • 1克強度

第9章 江之靈片市場依治療領域分類

  • 高血脂症
  • 高血壓

第10章 江之靈片市場（依生產商類型分類）

  • 學名藥
    • 國產學名藥
    • 進口學名藥
  • 原品牌

第11章 江之靈片市場通路

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 江之靈片劑市場（依最終用戶分類）

  • 成人
  • 老年人
  • 兒童

第13章 江之靈片市場區域分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 江之靈片市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 江之靈片市場各國狀況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國江之靈片市場

第17章：中國抗芝靈片市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anhui Shengkang Pharmaceutical Co., Ltd.
  • Beijing Tong Ren Tang Co., Ltd.
  • Harbin Pharmaceutical Group Co., Ltd.
  • Jiangsu Kanion Pharmaceutical Co., Ltd.
  • Jilin Yatai Pharmaceutical Co., Ltd.
  • Livzon Pharmaceutical Group Inc.
  • Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • Tasly Pharmaceutical Group Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Zhejiang Conba Pharmaceutical Co., Ltd.
Product Code: MRR-AE420CB153E5

The Jiangzhiling Tablets Market was valued at USD 93.86 million in 2025 and is projected to grow to USD 104.51 million in 2026, with a CAGR of 4.30%, reaching USD 126.03 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 93.86 million
Estimated Year [2026] USD 104.51 million
Forecast Year [2032] USD 126.03 million
CAGR (%) 4.30%

An insightful orientation that contextualizes Jiangzhiling tablets within clinical needs, formulation attributes, and the commercial landscape influencing strategic choices

Jiangzhiling tablets have emerged as a distinctive therapy within cardiovascular and metabolic treatment regimens, attracting attention from clinicians, payers, and manufacturers due to their formulation characteristics and targeted therapeutic use. As treatment paradigms evolve toward greater emphasis on patient adherence and differentiated release profiles, Jiangzhiling's positioning intersects clinical demand for sustained efficacy with commercial imperatives for reliable supply. This introduction frames the product in the broader context of therapeutic need, regulatory scrutiny, and distribution complexity, guiding readers through the salient considerations that underpin strategic decisions.

To set the stage for subsequent analysis, it is important to consider the interplay between formulation science and market reception. Clinical stakeholders increasingly prioritize products that deliver predictable pharmacokinetics while minimizing dosing burden, and manufacturers must navigate intellectual property landscapes, manufacturing scalability, and evolving quality expectations. Transitioning from therapeutic rationale to commercial realities, the remainder of this report unpacks the structural forces shaping Jiangzhiling's trajectory and translates them into actionable perspectives for executives and portfolio managers.

How regulatory rigor, channel diversification, and patient-centric formulation priorities are reshaping the commercial and clinical landscape for Jiangzhiling tablets

The landscape surrounding cardiovascular therapeutics and oral tablet formulations is undergoing transformative shifts driven by regulatory change, channel evolution, and heightened supply chain scrutiny. New manufacturing paradigms prioritize localized production resilience and compliance with increasingly stringent quality controls, while distribution pathways continue to fragment as digital channels gain traction. These shifts are reshaping how products like Jiangzhiling are developed, approved, and delivered to patients, requiring stakeholders to adapt across research, manufacturing, and commercialization functions.

Converging with manufacturing and channel dynamics, payer expectations and prescriber preferences are evolving toward evidence of real-world effectiveness and adherence benefits. Patient-centric design, including extended-release formulations that reduce dosing frequency, is influencing prescriber choice and formulary placement. Moreover, regulatory authorities are intensifying scrutiny of manufacturing consistency and supply chain traceability, prompting firms to invest in robust quality systems and supplier diversification. As a result, the competitive environment is no longer defined solely by clinical efficacy but also by an ability to demonstrate reliable supply, regulatory compliance, and measurable patient outcomes.

Assessing how tariff measures through 2025 have intensified supply chain recalibration, procurement strategy, and manufacturing localization decisions across the Jiangzhiling value chain

Tariff policies implemented by major economies through 2025 have introduced additional layers of complexity for pharmaceutical supply chains, affecting costs, sourcing decisions, and strategic manufacturing footprints. For products dependent on imported active pharmaceutical ingredients or finished dosage forms, tariff-related duties and associated compliance requirements have increased procurement overhead and prompted re-evaluation of supplier networks. In response, many manufacturers have accelerated supplier qualification initiatives and assessed the viability of nearshoring to mitigate exposure to trade policy volatility.

Beyond cost implications, tariffs have influenced decisions around inventory strategy and contractual terms with raw material providers. Firms have adjusted procurement lead times, increased safety stock in certain geographies, and negotiated price and delivery contingencies to preserve continuity of supply. Simultaneously, policy-driven shifts have altered competitive dynamics by favoring manufacturers with domestic production capabilities or vertically integrated supply chains. Taken together, the cumulative effect of tariff measures has been to sharpen focus on supply chain resilience, pricing strategy, and the strategic alignment of manufacturing footprints with key commercial markets.

A nuanced segmentation framework revealing how distribution pathways, patient cohorts, formulation types, therapeutic targets, and manufacturer profiles shape strategic priorities for Jiangzhiling

Understanding the Jiangzhiling tablets market requires a granular view of distribution, end-user segments, product typologies, therapeutic applications, and manufacturer archetypes, each of which exerts distinct influence on commercial strategy. Distribution channel dynamics span hospital pharmacies, online pharmacies, and retail pharmacies, with hospitals often driving institutional procurement cycles while online channels accelerate patient access and convenience. End-user considerations differentiate adults, geriatric patients, and pediatric populations, shaping clinical messaging, dosing regimens, and adherence programs.

Product type segmentation distinguishes extended-release tablets from standard tablets, and within those categories, strength variations such as 0.5 gram and 1 gram formulations have implications for prescribing patterns, dosing flexibility, and inventory management. Therapeutic area focus on hyperlipidemia and hypertension informs clinical positioning, evidence generation priorities, and payer negotiations. Manufacturer type, split between generics and original brands, further differentiates market behavior; generics can be sourced domestically or imported, which creates divergent cost structures, regulatory pathways, and market access strategies. By synthesizing these dimensions, stakeholders can identify where competitive advantage is most likely to emerge and which commercial levers will have the greatest impact on adoption and retention.

How regional regulatory diversity, reimbursement structures, and manufacturing capabilities influence tailored market entry and supply chain strategies for Jiangzhiling tablets

Regional dynamics materially influence regulatory pathways, reimbursement mechanisms, and supply chain design for Jiangzhiling tablets, with each geography presenting unique operational and commercial considerations. In the Americas, market behavior is influenced by a combination of regulatory rigor, payer negotiation intensity, and a high degree of distributor involvement, prompting firms to emphasize clinical evidence and robust pharmacovigilance to secure formulary placement. Conversely, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts coexist with fragmented reimbursement systems, requiring adaptive strategies that account for country-level variations in procurement and pricing.

Asia-Pacific markets exhibit diverse manufacturing capabilities and a strong emphasis on domestic production in several economies, alongside rapid growth in digital dispensing channels. These regional differences necessitate differentiated approaches: supply chain localization and partnership models for the Americas and Asia-Pacific, and flexible pricing and market access strategies for Europe, Middle East & Africa. Transitioning between regions, firms must balance centralized programmatic efficiencies with localized execution to address regulatory, commercial, and logistical nuances that affect uptake and sustainability.

Competitive landscape analysis emphasizing how original brands, domestic and imported generics, and formulation capabilities determine differentiation and commercial momentum

Competitive dynamics across the Jiangzhiling landscape are shaped by a mix of established original brands and an expanding generics sector, each driving different strategic imperatives. Original brands tend to concentrate on differentiated clinical evidence, lifecycle management, and premium positioning, while generics prioritize cost competitiveness, manufacturing efficiency, and broad distribution reach. Within the generics category, domestic producers often leverage lower operational costs and proximity to local procurement channels, whereas imported generics may differentiate on perceived quality, regulatory pedigree, or formulation expertise.

Firms that prioritize extended-release technologies are investing in formulation engineering and stability studies to support claims of improved adherence and pharmacokinetic benefits. Meanwhile, companies operating across multiple distribution channels are optimizing commercial models to address physician, institutional, and consumer touchpoints. Collaboration between manufacturers and channel partners is increasingly important, as coordinated efforts on educational programs, supply continuity, and regulatory compliance enhance both adoption and patient outcomes. Overall, competitive advantage emerges from a blend of technical capability, regulatory agility, and distribution execution.

Actionable strategic priorities for leaders to synchronize formulation innovation, supply chain resilience, and channel-focused commercial execution to secure competitive advantage

Industry leaders should pursue an integrated strategy that aligns formulation innovation, supply chain resilience, and targeted commercial execution to capture opportunity and mitigate risk. Prioritizing investment in extended-release formulation development can yield meaningful clinical and adherence advantages, but must be supported by rigorous stability testing and clear differentiation in clinical communication. At the same time, diversifying supplier networks and assessing nearshoring options will reduce exposure to trade policy volatility and enable more predictable lead times for active ingredients and finished products.

Commercially, optimizing channel strategies requires balancing institutional engagement with hospital pharmacies and tailored outreach to retail and online pharmacies to support both prescriber adoption and patient access. Manufacturers should also refine segmentation-based value propositions that reflect differences across adult, geriatric, and pediatric populations, and calibrate messaging for therapeutic contexts such as hyperlipidemia and hypertension. Finally, forming strategic alliances with distributors, contract manufacturers, and clinical research partners can accelerate market entry and strengthen compliance frameworks, delivering a robust platform for sustained growth.

A rigorous mixed-methods approach combining primary stakeholder engagement, secondary source triangulation, and scenario testing to ensure robust and defensible insights

The research methodology underpinning this analysis combines primary stakeholder engagement with comprehensive secondary synthesis to ensure a balanced and defensible understanding of the Jiangzhiling landscape. Primary inputs included structured interviews with clinical experts, supply chain managers, and commercial leaders to capture firsthand perspectives on prescribing behavior, procurement dynamics, and operational constraints. These qualitative insights were triangulated against regulatory documentation, publicly available clinical literature, and product labeling to validate technical and safety narratives.

Analytical rigor was maintained through cross-validation of data points, scenario analysis to test sensitivity to policy and supply disruptions, and iterative peer review by subject matter experts. The approach emphasized transparency in assumptions, systematic treatment of segmentation variables such as distribution channel, end-user cohorts, product typologies, therapeutic areas, and manufacturer categories, and quality assurance processes to verify consistency. Where gaps existed, targeted follow-up interviews and document reviews were executed to close informational deficits and ensure robust conclusions.

A strategic synthesis highlighting how formulation differentiation, supply chain robustness, and targeted commercialization combine to determine sustainable market outcomes for Jiangzhiling

In closing, the Jiangzhiling tablets landscape is defined by a confluence of formulation-driven clinical opportunities and commercially material operational challenges. Extended-release technologies and strength variations offer pathways to differentiate in therapeutic areas such as hyperlipidemia and hypertension, yet success depends on harmonizing clinical evidence, regulatory compliance, and dependable supply. Distribution channels and end-user heterogeneity further require nuanced go-to-market tactics that reconcile institutional procurement cycles with the increasing influence of retail and digital pharmacies.

Looking ahead, organizations that integrate formulation innovation with resilient manufacturing footprints and adaptive channel strategies will be best positioned to navigate policy shifts, supply chain disruptions, and heightened payer scrutiny. Effective execution will hinge on disciplined segmentation, targeted evidence generation, and collaborative partnerships that enhance both product differentiation and delivery reliability. These combined actions create a defensible path to sustained adoption and long-term commercial viability for Jiangzhiling tablets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Jiangzhiling Tablets Market, by Product Type

  • 8.1. Extended-Release Tablets
    • 8.1.1. 0.5G Strength
    • 8.1.2. 1G Strength
  • 8.2. Standard Tablets
    • 8.2.1. 0.5G Strength
    • 8.2.2. 1G Strength

9. Jiangzhiling Tablets Market, by Therapeutic Area

  • 9.1. Hyperlipidemia
  • 9.2. Hypertension

10. Jiangzhiling Tablets Market, by Manufacturer Type

  • 10.1. Generics
    • 10.1.1. Domestic Generics
    • 10.1.2. Imported Generics
  • 10.2. Original Brands

11. Jiangzhiling Tablets Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Jiangzhiling Tablets Market, by End User

  • 12.1. Adults
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Jiangzhiling Tablets Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Jiangzhiling Tablets Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Jiangzhiling Tablets Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Jiangzhiling Tablets Market

17. China Jiangzhiling Tablets Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anhui Shengkang Pharmaceutical Co., Ltd.
  • 18.6. Beijing Tong Ren Tang Co., Ltd.
  • 18.7. Harbin Pharmaceutical Group Co., Ltd.
  • 18.8. Jiangsu Kanion Pharmaceutical Co., Ltd.
  • 18.9. Jilin Yatai Pharmaceutical Co., Ltd.
  • 18.10. Livzon Pharmaceutical Group Inc.
  • 18.11. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  • 18.12. Tasly Pharmaceutical Group Co., Ltd.
  • 18.13. Yunnan Baiyao Group Co., Ltd.
  • 18.14. Zhejiang Conba Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL JIANGZHILING TABLETS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL JIANGZHILING TABLETS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 0.5G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY 1G STRENGTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERLIPIDEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DOMESTIC GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY IMPORTED GENERICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ORIGINAL BRANDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. GCC JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 152. GCC JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. G7 JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. G7 JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 178. G7 JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 179. G7 JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. G7 JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. NATO JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 188. NATO JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. NATO JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL JIANGZHILING TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA JIANGZHILING TABLETS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA JIANGZHILING TABLETS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA JIANGZHILING TABLETS MARKET SIZE, BY EXTENDED-RELEASE TABLETS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA JIANGZHILING TABLETS MARKET SIZE, BY STANDARD TABLETS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA JIANGZHILING TABLETS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA JIANGZHILING TABLETS MARKET SIZE, BY MANUFACTURER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA JIANGZHILING TABLETS MARKET SIZE, BY GENERICS, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA JIANGZHILING TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA JIANGZHILING TABLETS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)